Literature DB >> 192812

Slow virus infection: replication and mechanisms of persistence of visna virus in sheep.

O Narayan, D E Griffin, A M Silverstein.   

Abstract

The influence of the age and immune status of the host on the slow replication and persistence of visna virus in sheep was studied. Twenty-five randomly bred fetal American lambs were inoculated intracerebrally with visna virus. Eight of these fetuses were immunosuppressed by thymectomy and antiserum to lymphocytes before inoculation. Fetuses were sacrificed sequentially, and tissues were processed for viral quantitation. No exponential increase of virus occurred in either the normal or immunosuppressed fetuses, and virus was recovered mainly by explanation of tissues. This finding indicated that the viral genome was present in tissue cells but that the extent of replication in the early phase of infection was restricted by factors unassociated with maturation or immune status of the host. In addition, virus isolated from the peripheral blood leukocytes of a sheep one year after inoculation was antigenically distinct from the plaque-purified virus used for inoculation. This distinction suggested that a major antigenic shift of the agent had occurred and provided another mechanism for the maintenance of the persistent infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192812     DOI: 10.1093/infdis/135.5.800

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology.

Authors:  Sheila A Barber; Linda Bruett; Brian R Douglass; David S Herbst; M Christine Zink; Janice E Clements
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 2.  Lentiviruses are etiological agents of chronic diseases in animals and acquired immunodeficiency syndrome in humans.

Authors:  O Narayan
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

3.  Characterization of a cDNA clone encoding the visna virus transactivating protein.

Authors:  J L Davis; J E Clements
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Modulation of lentivirus replication by antibodies: Fc portion of immunoglobulin molecule is essential for enhancement of binding, internalization, and neutralization of visna virus in macrophages.

Authors:  P E Jolly; D L Huso; D Sheffer; O Narayan
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  Murine neurotropic retrovirus spongiform polioencephalomyelopathy: acceleration of disease by virus inoculum concentration.

Authors:  B R Brooks; J R Swarz; O Narayan; R T Johnson
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

6.  Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus.

Authors:  O Narayan; J E Clements; D E Griffin; J S Wolinsky
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

7.  Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism.

Authors:  L Bruett; J E Clements
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Lentiviruses are naturally resident in a latent form in long-term ovine fibroblast cultures.

Authors:  V Barban; G Quérat; N Sauze; P Filippi; R Vigne; P Russo; C Vitu
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

9.  Genetic variation among lentiviruses: homology between visna virus and caprine arthritis-encephalitis virus is confined to the 5' gag-pol region and a small portion of the env gene.

Authors:  J M Pyper; J E Clements; S M Molineaux; O Narayan
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

10.  Targeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo.

Authors:  B A Morse; L M Carruth; J E Clements
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.